Skip to main content
Top
Published in: Lung 2/2017

01-04-2017 | Interstitial lung disease

Volatile Organic Compounds in Exhaled Breath of Idiopathic Pulmonary Fibrosis for Discrimination from Healthy Subjects

Authors: Yu-ichi Yamada, Gen Yamada, Mitsuo Otsuka, Hirotaka Nishikiori, Kimiyuki Ikeda, Yasuaki Umeda, Hirofumi Ohnishi, Koji Kuronuma, Hirofumi Chiba, Jörg Ingo Baumbach, Hiroki Takahashi

Published in: Lung | Issue 2/2017

Login to get access

Abstract

Purpose Human breath analysis is proposed with increasing frequency as a useful tool in clinical application. We performed this study to find the characteristic volatile organic compounds (VOCs) in the exhaled breath of patients with idiopathic pulmonary fibrosis (IPF) for discrimination from healthy subjects. Methods VOCs in the exhaled breath of 40 IPF patients and 55 healthy controls were measured using a multi-capillary column and ion mobility spectrometer. The patients were examined by pulmonary function tests, blood gas analysis, and serum biomarkers of interstitial pneumonia. Results We detected 85 VOC peaks in the exhaled breath of IPF patients and controls. IPF patients showed 5 significant VOC peaks; p-cymene, acetoin, isoprene, ethylbenzene, and an unknown compound. The VOC peak of p-cymene was significantly lower (p < 0.001), while the VOC peaks of acetoin, isoprene, ethylbenzene, and the unknown compound were significantly higher (p < 0.001 for all) compared with the peaks of controls. Comparing VOC peaks with clinical parameters, negative correlations with VC (r =−0.393, p = 0.013), %VC (r =−0.569, p < 0.001), FVC (r = −0.440, p = 0.004), %FVC (r =−0.539, p < 0.001), DLco (r =−0.394, p = 0.018), and %DLco (r =−0.413, p = 0.008) and a positive correlation with KL-6 (r = 0.432, p = 0.005) were found for p-cymene. Conclusion We found characteristic 5 VOCs in the exhaled breath of IPF patients. Among them, the VOC peaks of p-cymene were related to the clinical parameters of IPF. These VOCs may be useful biomarkers of IPF.
Appendix
Available only for authorised users
Literature
1.
go back to reference King TE Jr, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. The Lancet 378:1949–1961CrossRef King TE Jr, Pardo A, Selman M (2011) Idiopathic pulmonary fibrosis. The Lancet 378:1949–1961CrossRef
2.
4.
go back to reference Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed
5.
go back to reference Rattray NJ, Hamrang Z, Trivedi DK et al (2014) Taking your breath away: metabolomics breathes life in to personalized medicine. Trends Biotechnol 32:538–548CrossRefPubMed Rattray NJ, Hamrang Z, Trivedi DK et al (2014) Taking your breath away: metabolomics breathes life in to personalized medicine. Trends Biotechnol 32:538–548CrossRefPubMed
6.
go back to reference Westhoff M, Litterst P, Maddula S et al (2010) Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry. Int J Ion Mobility Spectrum 13:131–139CrossRef Westhoff M, Litterst P, Maddula S et al (2010) Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry. Int J Ion Mobility Spectrum 13:131–139CrossRef
7.
go back to reference Van Berkel JJ, Dallinga JW, Möller GM et al (2010) A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 104:557–567CrossRefPubMed Van Berkel JJ, Dallinga JW, Möller GM et al (2010) A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 104:557–567CrossRefPubMed
8.
go back to reference Besa V, Teschler H, Kurth I et al (2015) Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int J Chron Obstruct Pulmon Dis 10:399–406PubMedPubMedCentral Besa V, Teschler H, Kurth I et al (2015) Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. Int J Chron Obstruct Pulmon Dis 10:399–406PubMedPubMedCentral
9.
go back to reference Dragonieri S, Schot R, Mertens BJ et al (2007) An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 120:856–862CrossRefPubMed Dragonieri S, Schot R, Mertens BJ et al (2007) An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 120:856–862CrossRefPubMed
10.
go back to reference Bunkowski A, Boedeker B, Bader S et al (2009) MCC/IMS signals in human breath related to sarcoidosis: results of a feasibility study using an automated peak finding procedure. J Breath Res 3:046001CrossRefPubMed Bunkowski A, Boedeker B, Bader S et al (2009) MCC/IMS signals in human breath related to sarcoidosis: results of a feasibility study using an automated peak finding procedure. J Breath Res 3:046001CrossRefPubMed
11.
go back to reference Westhoff M, Litterst P, Freitag L et al (2007) Ion mobility spectrometry in the diagnosis of sarcoidosis: Results of a feasibility study. J Physiol Pharmacol 58:739–751PubMed Westhoff M, Litterst P, Freitag L et al (2007) Ion mobility spectrometry in the diagnosis of sarcoidosis: Results of a feasibility study. J Physiol Pharmacol 58:739–751PubMed
12.
go back to reference Phillips M, Cataneo RN, Condos R et al (2007) Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 87:44–52CrossRefPubMed Phillips M, Cataneo RN, Condos R et al (2007) Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 87:44–52CrossRefPubMed
13.
go back to reference Phillips M, Basa-Dalay V, Blais J et al (2012) Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis 92:314–320CrossRefPubMed Phillips M, Basa-Dalay V, Blais J et al (2012) Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis 92:314–320CrossRefPubMed
14.
15.
go back to reference McGrath LT, Patrick R, Mallon P et al (2000) Breath isoprene during acute respiratory exacerbation in cystic fibrosis. Eur Respir J 16:1065–1069CrossRefPubMed McGrath LT, Patrick R, Mallon P et al (2000) Breath isoprene during acute respiratory exacerbation in cystic fibrosis. Eur Respir J 16:1065–1069CrossRefPubMed
16.
go back to reference Cakir Y, Métraillier L, Baumbach JI et al (2014) Signals in asbestos related diseases in human breath—preliminary results. Int J Ion Mobil Spec 17:87–94CrossRef Cakir Y, Métraillier L, Baumbach JI et al (2014) Signals in asbestos related diseases in human breath—preliminary results. Int J Ion Mobil Spec 17:87–94CrossRef
17.
go back to reference Philips M, Cataneo RN, Cummin ARC et al (2003) Detection of lung cancer with volatile markers in the breath. Chest 123:2115–2123CrossRef Philips M, Cataneo RN, Cummin ARC et al (2003) Detection of lung cancer with volatile markers in the breath. Chest 123:2115–2123CrossRef
18.
go back to reference Machado RF, Raskowski D, Deffenderfer O et al (2005) Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 171:1286–1291CrossRefPubMedPubMedCentral Machado RF, Raskowski D, Deffenderfer O et al (2005) Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 171:1286–1291CrossRefPubMedPubMedCentral
19.
go back to reference Westhoff M, Litterst P, Freitag L et al (2009) Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 64:744–748CrossRefPubMed Westhoff M, Litterst P, Freitag L et al (2009) Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 64:744–748CrossRefPubMed
20.
go back to reference Darwiche K, Baumbach JI, Sommerwerck U et al (2011) Bronchoscopically obtained volatile biomarkers in lung cancer. Lung 189:445–452CrossRefPubMed Darwiche K, Baumbach JI, Sommerwerck U et al (2011) Bronchoscopically obtained volatile biomarkers in lung cancer. Lung 189:445–452CrossRefPubMed
21.
go back to reference Kanoh S, Kobayashi H, Motoyoshi K (2005) Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 128:2387–2392CrossRefPubMed Kanoh S, Kobayashi H, Motoyoshi K (2005) Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 128:2387–2392CrossRefPubMed
22.
go back to reference Buszewski B, Grzywinski D, Ligor T et al (2013) Detection of volatile organic compounds as biomarkers in breath analysis by different analytical techniques. Bioanalysis 5: 2287–2306CrossRefPubMed Buszewski B, Grzywinski D, Ligor T et al (2013) Detection of volatile organic compounds as biomarkers in breath analysis by different analytical techniques. Bioanalysis 5: 2287–2306CrossRefPubMed
23.
go back to reference Baumbach JI (2009) Ion mobility spectrometry coupled with multi-capillary columns for metabolic profiling of human breath. J Breath Res 3:034001CrossRefPubMed Baumbach JI (2009) Ion mobility spectrometry coupled with multi-capillary columns for metabolic profiling of human breath. J Breath Res 3:034001CrossRefPubMed
24.
go back to reference Hauschild AC, Schneider T, Pauling J et al (2012) Computational methods for metabolomic data analysis of ion mobility spectrometry data-reviewing the state of art. Metabolites 2: 733–755CrossRefPubMedPubMedCentral Hauschild AC, Schneider T, Pauling J et al (2012) Computational methods for metabolomic data analysis of ion mobility spectrometry data-reviewing the state of art. Metabolites 2: 733–755CrossRefPubMedPubMedCentral
25.
go back to reference Fink T, Baumbach JI, Kreuer S (2014) Ion mobility spectrometry in breath research. J Breath Res 8:027104CrossRefPubMed Fink T, Baumbach JI, Kreuer S (2014) Ion mobility spectrometry in breath research. J Breath Res 8:027104CrossRefPubMed
27.
go back to reference Cumeras R, Figueras E, Davis CE et al (2015) Review on ion mobility spectrometry. Part 2: hyphenated methods and effects of experimental parameters. Analyst 140:1391–1410CrossRefPubMedPubMedCentral Cumeras R, Figueras E, Davis CE et al (2015) Review on ion mobility spectrometry. Part 2: hyphenated methods and effects of experimental parameters. Analyst 140:1391–1410CrossRefPubMedPubMedCentral
28.
go back to reference Foster WM, Jiang L, Stetkiewicz PT et al (1996) Breath isoprene: temporal changes in respiratory output after exposure to ozone. J Appl Physiol 80:706–710PubMed Foster WM, Jiang L, Stetkiewicz PT et al (1996) Breath isoprene: temporal changes in respiratory output after exposure to ozone. J Appl Physiol 80:706–710PubMed
29.
go back to reference Jalali M, Zare Sakhvidi MJ, Bahrami A et al (2016) Oxidative stress biomarkers in exhaled breath of workers exposed to crystalline silica dust by SPME-GC-MS. J Res Health Sci 16:153–161PubMed Jalali M, Zare Sakhvidi MJ, Bahrami A et al (2016) Oxidative stress biomarkers in exhaled breath of workers exposed to crystalline silica dust by SPME-GC-MS. J Res Health Sci 16:153–161PubMed
30.
go back to reference Cheresh P, Kim SJ, Tulasiram S et al (2013) Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 1832: 1028–1040CrossRefPubMed Cheresh P, Kim SJ, Tulasiram S et al (2013) Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 1832: 1028–1040CrossRefPubMed
31.
go back to reference Chan PC, Haseman JK, Mahleri J et al (1998) Tumor induction in F344/N rats and B6C3F1 mice following inhalation exposure to ethylbenzene. Toxicol Lett 99:23–32CrossRefPubMed Chan PC, Haseman JK, Mahleri J et al (1998) Tumor induction in F344/N rats and B6C3F1 mice following inhalation exposure to ethylbenzene. Toxicol Lett 99:23–32CrossRefPubMed
32.
go back to reference Saghir SA, Zhang F, Rick DL et al (2010) In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul Toxicol Pharmacol 57:129–135CrossRefPubMed Saghir SA, Zhang F, Rick DL et al (2010) In vitro metabolism and covalent binding of ethylbenzene to microsomal protein as a possible mechanism of ethylbenzene-induced mouse lung tumorigenesis. Regul Toxicol Pharmacol 57:129–135CrossRefPubMed
33.
34.
go back to reference Song G, Qin T, Liu H et al (2010) Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 67:227–231CrossRefPubMed Song G, Qin T, Liu H et al (2010) Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 67:227–231CrossRefPubMed
35.
go back to reference Xie G, Chen N, Soromou LW et al (2012) p-Cymene protects mice against lipopolysaccharide-induced acute lung injury by inhibiting inflammatory cell activation. Molecules 17:8159–8173CrossRefPubMed Xie G, Chen N, Soromou LW et al (2012) p-Cymene protects mice against lipopolysaccharide-induced acute lung injury by inhibiting inflammatory cell activation. Molecules 17:8159–8173CrossRefPubMed
Metadata
Title
Volatile Organic Compounds in Exhaled Breath of Idiopathic Pulmonary Fibrosis for Discrimination from Healthy Subjects
Authors
Yu-ichi Yamada
Gen Yamada
Mitsuo Otsuka
Hirotaka Nishikiori
Kimiyuki Ikeda
Yasuaki Umeda
Hirofumi Ohnishi
Koji Kuronuma
Hirofumi Chiba
Jörg Ingo Baumbach
Hiroki Takahashi
Publication date
01-04-2017
Publisher
Springer US
Published in
Lung / Issue 2/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-9979-3

Other articles of this Issue 2/2017

Lung 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine